Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an Immune-Boosting herb improve colorectal cancer survival?

NCT ID NCT07703709

Disease control Sponsor: Chou-Chen Chen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study looks at whether adding an immune-modulating drug called Astragalus polysaccharide (APS) to standard cancer treatments can help people with colorectal cancer live longer. The drug is already approved in Taiwan for cancer-related fatigue. Researchers will review medical records of 60 patients to compare outcomes between those who received APS plus standard therapy and those who received standard therapy alone. The goal is to see if APS improves overall survival and other measures like disease-free survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an immunomodulator called Astragalus polysaccharide (APS) Injection
What this could lead to
If adding APS to standard therapy improves survival, it could offer a new, well-tolerated option for colorectal cancer treatment.
What could go wrong
This is a real-world study, not a randomized trial, so results may be influenced by patient selection. The benefit of APS in colorectal cancer is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with and treated for colorectal cancer at Cheng Ching General Hospital, Chung Kang Branch, Taiwan

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 20 years and older * Patients who have been given a diagnosis of colorectal cancer * Patients had previously initiated anti-cancer therapies between Jan 01 2025 and Dec 31, 2027 Exclusion Criteria: * Non

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Survival , tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cheng Ching General Hospital, Chung Kang Branch

    RECRUITING

    Taichung, 40764, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.